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SUMMARY
The post-genomics era has provided researchers with access to a new generation of tools for the global characterization and
understanding of pathogen diversity. This review provides a critical summary of published Leishmania post-genomic
research eﬀorts to date, and discusses the potential impact of the addition of metabolomics to the post-genomic toolbox.
Metabolomics aims at understanding biology by comprehensive metabolite proﬁling.We present an overview of the design
and interpretation of metabolomics experiments in the context of Leishmania research. Sample preparation, measurement
techniques, and bioinformatics analysis of the generated complex datasets are discussed in detail. To illustrate the concepts
and the expected results of metabolomics analyses, we also present an overview of comparative metabolic proﬁles of
drug-sensitive and drug-resistant Leishmania donovani clinical isolates.
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THE CHALLENGE OF LEISHMANIA DIVERSITY
Leishmania is a group of kinetoplastid protozoa with
a highly diverse character. The genus includes more
than 20 parasite species infecting humans following
transmission by a sand ﬂy (Diptera: Psychodidae:
Phlebotominae). All species are pathogenic, but the
disease manifestation depends on the infecting
species and varies from self-healing skin lesions, to
disﬁguring mucocutaneous lesions, to lethal visceral
disease. Even a single Leishmania species can chal-
lenge health professionals with enormous clinical
diversity; disease severity can vary greatly between
diﬀerent patients, variable response or lack of re-
sponse to administered treatments is often observed,
and post-leishmaniasis syndrome can appear in
some, but not all cases. This clinical polymorphism
results from the interaction between several factors,
including variation in the host, parasite, vector, and
environment (Dujardin, 2009). Hardly anything is
known about the nature and identity of the intra-
and inter-species molecular diﬀerences underlying
the clinical polymorphism in leishmaniases (Smith
et al. 2007). Diversity also marks the Leishmania
life cycle, which consists of two distinct life-forms,
promastigotes and amastigotes, adapted to life in a
sand ﬂy vector and mammalian host, respectively.
The transformation from promastigote to amastigote
is essential for the parasite’s survival upon trans-
mission from vector to host. How Leishmania dif-
ferentiates between life stages, and which metabolic
pathways are essential for survival within each host,
are pressing questions requiring an answer in order
to develop more eﬀective treatments and alternative
control measures against these pathogens in the face
of ever increasing resistance to the few available
drugs (McConville et al. 2007). A detailed molecular
characterization of parasite diversity and the under-
lying biology, including mechanisms of drug resist-
ance, is therefore a pressing need.
Whole-genome sequencing, transcriptomics
studies based on whole genome-based DNA arrays,
and global proteomic studies have already been
carried out in an eﬀort to characterize Leishmania
diversity. Now, the toolbox of post-genomic research
has been complemented by metabolomics, which
involves global analysis of the metabolites in a cell
(i.e. the metabolome) (Fernie et al. 2004; Goodacre
et al. 2004). Metabolomics is an emerging ﬁeld in
functional genomics that is complementary to the
other post-genomic technologies and potentially a
powerful tool in its own right to characterize
Leishmania diversity. This review starts by providing
a critical summary of published Leishmania post-
genomic research eﬀorts that have scrutinized
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Leishmania diversity. Secondly, we will discuss in
detail the opportunities and challenges of a metab-
olomics approach speciﬁcally for Leishmania re-
search, focusing on the critical issues of sample
preparation, measurement optimization, and setting
up an eﬃcient bioinformatics pipeline for processing
the complex data generated. Finally, we will brieﬂy
discuss how an integrated approach combining
information across all molecular levels holds the
greatest potential for understanding parasite biology
and successfully developing improved control strat-
egies for the debilitating diseases they cause.
CURRENT CONTRIBUTION OF GENOME,
TRANSCRIPTOME AND PROTEOME STUDIES
The whole genomes of L. major, L. infantum and
L. braziliensis have been sequenced and compara-
tively analyzed (Peacock et al. 2007). Despite the
broad diﬀerences in disease pathologies, it appears
that the three genomes have a highly conserved gene
content, synteny and genome architecture, and only
very few genes are species-speciﬁc in each genome
(5, 26 and 47, respectively). The authors concluded
that either (1) a few species-speciﬁc genes determine
pathogenesis, or (2) the parasite genome plays only
a minor role in determining clinical proﬁle, or
(3) parasite gene/protein expression levels diﬀer con-
siderably between species, possibly as a consequence
of gene dosage in the form of gene copy number
variation. The latter hypothesis is supported by
comparative studies of Leishmania species (benign
cutaneous L. peruviana vs severe cutaneous L. bra-
ziliensis) and strains with diﬀerential pathogenicity
(cutaneous L. infantum vs visceral L. infantum) : in
both cases, it was shown that the less pathogenic
parasites presented fewer copies of ribosomal DNA
(aﬀecting general metabolism) and genes encoding
surface antigens (aﬀecting interaction with host cells)
compared to the more pathogenic parasites (Victoir
et al. 1995; Inga et al. 1998; Guerbouj et al. 2001;
Dujardin, 2009). A similar gene-dosage-related
phenomenon has repeatedly been described in the
context ofLeishmania drug resistance. Chromosomes
containing genes with a functional role in drug re-
sistance were ampliﬁed in drug resistant strains,
showing polyploidy of the complete chromosome
or partial ampliﬁcation of speciﬁc regions as extra-
chromasomal circular or linear amplicons; this in
turn results in up-regulated expression of those
ampliﬁed genes (Ubeda et al. 2008; Ouellette et al.
2009; Leprohon et al. 2009). Hence, Leishmania
diversity could very well be encoded by gene
copy number variation, either intra- or extra-
chromosomal. The three-genome project however,
was limited with respect to characterization of copy
number variation (gene dosage), as the Sanger se-
quencing technique used in the project starts with
cloned genomic DNA fragments that are ﬁrst
ampliﬁed in vivo (Sturm et al. 2008). Meanwhile
new sequencing technologies have been developed
that can circumvent this limitation (Hall, 2007;
Morozova et al. 2008). In addition to the relatively
low cost and high-throughput capacity, these new
technologies oﬀer the advantage of generating se-
quence data that can be used in a sequence census
approach. The sequence census approach involves
mapping of all sequence reads to its origin in a ref-
erence genome; the number of reads that map to a
particular nucleic acid species then correlates with
the abundance of that sequence in the cell. This
allows comparison of gene dosage at a particular
locus in diﬀerent strains (Morozova et al. 2008). In
the near future, this new genomic approach is likely
to clarify the role gene dosage plays in generating
Leishmania diversity.
Transcriptomics studies have used Leishmania-
speciﬁc microarrays to assay steady-state levels of
mRNA transcripts. Arrays with a genome coverage
between 22% and 97.5% have been used to determine
diﬀerences in expression between diﬀerent life-
cycle stages (Holzer et al. 2006; Leifso et al. 2007;
Saxena et al. 2007; Srividya et al. 2007; Rochette
et al. 2008), to determine expression diﬀerences as-
sociated with drug resistance (Guimond et al. 2003;
Singh et al. 2007; Fadili et al. 2009) and clinical
polymorphisms (Salotra et al. 2006; Singh et al.
2007), and to assess expression diﬀerences between
diﬀerent species (Rochette et al. 2008). However, all
these transcriptomics proﬁling eﬀorts provided few
insights compared to experiences with other mi-
crobial pathogens. It seems that due to at least two
speciﬁc factors of Leishmania biology, transcript-
omics is a strikingly uninformative tool to uncover
the molecular background of Leishmania diversity.
Firstly, Leishmania uses polycistronic transcription
and very few promoters, and regulation appears to
occur at the post-transcriptional level (McDonagh
et al. 2000; Cohen-Freue et al. 2007; Clayton and
Shapira, 2007). As a consequence, studies compar-
ing diﬀerent life stages found that indeed the vast
majority of genes are constitutively expressed in all
development stages. Only a limited number of genes
(2–9%) show preferential stage-speciﬁc expression,
and those quantitative expression changes are often
very small and not always easy to detect reproducibly
(Cohen-Freue et al. 2007). Secondly, although the
Leishmania genome sequencing project is complete,
more than 60% of the putative protein coding genes
do not match annotated sequences and were assigned
a hypothetical function (Ivens et al. 2005). Hence,
the majority of identiﬁed diﬀerentially expressed
genes in any of the above mentioned genome-
wide transcriptomics studies turn out to have an
unknown biological function. Thus so far, tran-
scriptomics has made a modest contribution in un-
ravelling the cell biological story behind Leishmania
diversity, as both the function of the identiﬁed
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proteins and their regulation can not always be ad-
equately assessed.
Proteomic studies have been particular useful for
the identiﬁcation of stage-speciﬁc proteins. Given
the characteristic expression regulation mechanisms
of Leishmania, it was not surprising that, compared
with the transcriptomics work, proteomic studies
reported a higher percentage (12–18%) of the pre-
dicted proteome as stage-speciﬁcally regulated at
the translational or post-translation level (Bente
et al. 2003; McNicoll et al. 2006; Leifso et al. 2007;
Cohen-Freue et al. 2007; Rosenzweig et al. 2008).
Most of these studies were based on two-dimensional
gel electrophoresis; recently the isobaric tagging
technique iTRAQ was successfully introduced and
proved to be an elegant method for proteomic time-
series experiments (Rosenzweig et al. 2008). The
study proﬁled 931 proteins over 7 life-cycle diﬀer-
entiation time points, which allowed the inference of
a map of the dynamics of most major metabolic
pathways during diﬀerentiation from promastigotes
to amastigotes in L. donovani. Proteomics is less re-
warding when studying phenotypic or pathologic
diversity. Like transcriptomics, proteomic ap-
proaches that studied mechanisms of drug resistance
(Sharma et al. 2003; Drummelsmith et al. 2003,
2004; Vergnes et al. 2007; Singh et al. 2008; Fadili
et al. 2009) or species diversity (Brobey et al. 2006)
very often resulted in a list of diﬀerentially expressed
proteins lacking an annotated function. This again
impedes determination of how the diﬀerent actors
relate to each other and often leaves too many open
questions.
THE POTENTIAL OF METABOLOMICS
In order to fully understand the phenotypic charac-
teristics of an organism, it is essential to complement
transcriptome and proteome research with metab-
olomics investigations. The sequenced genome of
L. major has already been used to predict the
metabolic potential of the organism in two diﬀerent
studies (Chavali et al. 2008; Doyle et al. 2009). Both
studies report around 1000 predicted metabolites,
all located in core metabolism, and associated to
as many enzyme-catalyzed reactions. As cell-based
metabolomics encompasses the diﬀerent cellular
compartments, this number of metabolites can be
reduced to around 600, correcting for themetabolites
occurring in multiple compartments within the cell.
Changes in protein and transcript levels often
function as intermediate steps leading to functionally
relevant variation at the metabolite level. It is at the
metabolite level that most physiological functions
are carried out, making the metabolome the closest
correlate to the phenotype (Fig. 1). Metabolite levels
are not easily predicted by protein or transcript
levels due to the highly non-local control structure
of the metabolic network (e.g. enzyme inhibitors
functioning at distant points in the metabolic net-
work), as revealed bymetabolic control analysis (Kell
and Westerhoﬀ, 1986), and thus require separate
investigation. The existence of metabolic maps
(Baxevanis et al. 2002; Kanehisa et al. 2002) allows
for rapid visualization of metabolite changes and
determination of the biological impact of the studied
conditions on the organism (e.g. which pathways
are aﬀected in drug resistant strains).
Research at the metabolic level is particularly
relevant for parasite biology, where metabolic
processes are among the major drug targets (for
example: dihydrofolate reductase (Methotrexate),
ergosterol (Amphotericin B), sterol biosynthesis
(azoles), phospholipidmetabolism (Miltefosine), and
polyamine biosynthesis (Eﬂornithine)). More gen-
erally, it was found that profound metabolic dis-
turbances underlie the lethal eﬀects of almost all
drugs. Metabolomics will not only allow for a better
understanding of the basic biological processes
already partly addressed by transcriptome and pro-
teome studies, but can also be applied to identify
metabolic signatures associated with pharmaceutical
interventions. Metabolomics allows both (1) pro-
















Fig. 1. A rough hypothetical sketch of the progressive
variability predicted across molecular levels when moving
from Leishmania genotype to phenotype. The arrows
indicate the predominant chain of causal inﬂuence
between the levels. (1) The genome is the most stable
molecular player of the system, but even at this level
ploidy changes and copy number variation might
introduce variability in a species and between species
(personal communication J. C. Dujardin). (2) Gene
expression studies comparing diﬀerent Leishmania life
stages or phenotypes, have found that 2–9% of all genes
are diﬀerentially expressed, while over 90% of genes
seem to be constitutively expressed (Cohen-Freue et al.
2007). (3) Similar studies based on two-dimensional gel
electrophoresis work have found that 5–12% of detected
proteins are diﬀerentially expressed (Cohen-Freue et al.
2007). (4) We predict that the metabolome will be
aﬀected to an even greater degree: due to the high
connectivity in the metabolic network and multiple
metabolites are linked to single enzymes, changes in
protein levels are likely to propagate across the
metabolome. (5) Ultimately the changes at the molecular
level are reﬂected in the diverse clinical phenotypes of
Leishmania infections (indicated here as phenotype A
and B).
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(often unknown) mode of action of eﬀective
antiparasitic drugs, and (2) proﬁling the adapted
metabolism of drug-resistant parasites. Metabolic
biomarkers could ultimately be reliable predictors
of treatment outcome and related clinical poly-
morphism, in particular because the concentration
of metabolites integrates changes happening at both
the genomic and environmental level. The eﬀec-
tiveness of metabolomics for signature identiﬁcation
is illustrated in Fig. 2A, which depicts the results
of an untargeted metabolomics comparison of drug-
resistant and drug-sensitive strains, using metabolite
extracts from L. donovani cultures measured on an
LTQ Orbitrap mass spectrometer combined with
HILIC liquid chromatography (Decuypere et al.
unpublished). Resistant and sensitive strains are
clearly separated on the ﬁrst principal component
(explaining 54.4% of the total variance), as over
40% of the identiﬁed metabolites show changes of
larger than two-fold between the two phenotypes
(Fig. 2B). A large portion of these changes is located
on well understood pathways involving amino acids
(and derivatives) and lipids (Fig. 2C), suggesting
hypotheses on the biological impact of the change
towards drug resistance. The diﬀerence between
strains is also clearly evident in a heatmap represent-
ation based on an unsupervised hierarchical cluster-
ing of the same metabolomics data (Fig. 3).
SAMPLE PREPARATION
Production of reproducible cell cultures and reliable,
quantitative extraction of metabolites is the most
vital step of any metabolomics study. It is also very
challenging, as, for example, the presence of con-
tamination or other confounding factors during
sample preparation will likely inﬂuence the outcome
of the experiment. The lack of well-designed exper-
imental metabolomics reference studies on parasites
makes this task even more challenging. The close
causal relation between the metabolome and the
phenotype makes the metabolome susceptible to
any changes in growth conditions (medium, tem-
perature, growth rate, etc.), making it diﬃcult to




























































































Fig. 2. Principal component analysis can be used to visualize the data so that the measured variation between samples
is maximally visible; here it successfully distinguishes drug-sensitive and drug-resistant samples. (A) Each set of
biological and technical replicates is clustered closely together, indicating that cell cultures were reproducibly generated
and extracted. Principal component 1 clearly separates the two phenotypes and explains 54.4% of the total variance,
while principal component 2 separates the diﬀerent experiments (samples 1 vs samples 2) and explains 12.1% of the
total variance. (B) The distribution of fold-changes between sensitive and resistant strains shows that a number of
metabolites exhibit large, almost binary (>10-fold) diﬀerences between the two phenotypes. A total of 49 (41.1%)
metabolites show diﬀerence of more than 2-fold. (C) Zooming in on the diﬀerences per metabolite class shows
variability of the relative expression in sensitive vs resistant strains across diﬀerent metabolite classes.
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obtain reproducible cell cultures. When comparing
several strains on a global metabolite level at one
particular growth stage, it is an absolute necessity
to collect samples from parasite cultures perfectly
synchronised to be at the same stage of growth. In
order to monitor the events at the metabolic level
in more detail, each study should include time course
based comparisons. This approach will ultimately
also help to visualise metabolite dynamics.
In general, metabolite extracts used for metab-
olomics should contain as many diﬀerent metabolites
as possible, of diﬀerent chemical classes, in their
original state, and in a quantitative and non-biased
manner (Dunn et al. 2005;Lu et al. 2008).Quenching
and cell permeabilization are necessities for achiev-
ing this, as they guarantee an accurate snapshot of
the physiological conditions of intracellular metab-
olites. The quenching procedure eﬀectively stops
metabolism in all the cells in the culture and needs
to act rapidly, as the turnover of biologically
important metabolites, such as ATP or NADH, can
be in the order of ﬂuxes of millimoles per litre per
second in living cells (Winder et al. 2008). Great care
also needs to be exercised as seemingly innocuous
steps such as centrifugation or washing the cells can
lead to drastic alterations in intracellular metabolite
levels. Quenching is usually done by rapidly chang-
ing the cell temperature or pH. For single-cell
species such as Leishmania several methods exist,
including: rapid ﬁltration through an ultraﬁltration
membrane and subsequent ﬂash-freezing in liquid
nitrogen (Wittmann et al. 2004), or, more frequently,
dilution of cells in cold organic solvent (e.g. meth-
anol, glycerol), with or without buﬀer (Faijes et al.
2007; Villas-Boˆas and Bruheim, 2007; Sellick et al.
2009). Due to chemical and physical dissimilarities
between the cell envelopes of single cell organisms,
these approaches do not work equally well for all
organisms. Leakage of intracellular metabolites, for
example, is practically unavoidable (Winder et al.
0 20 40 60 80
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Fig. 3. Hierarchical clustering shows clear separation of the metabolite proﬁles of sensitive and resistant strains.
As an alternative to PCA, the unsupervised hierarchical clustering method can be used to visualise the metabolite
expression levels. The similarity of samples is assessed by calculating the correlation between their metabolite proﬁles
(detected intensity levels), and samples that are more similar are closer in the tree. This method shows that large
diﬀerences between sensitive and resistant strains are observed for almost all the metabolite classes.
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2008) and can have a strong impact on the observed
metabolite concentrations in the extract.
Due to the vast chemical variability of metabolites,
covering the complete metabolome in a single ex-
periment is practically impossible. Procedures for
non-targeted metabolite extraction focus mainly on
obtaining the largest possible representation of rel-
evant metabolites. As parasite cells tend to easily
burst when organic solvents are added, hot ethanol
extraction (Kamleh et al. 2008), and chloroform/
methanol/water extraction (De Souza et al. 2006) are
the current methods of choice for untargeted metab-
olomics in protozoan parasites. When lipids are tar-
geted, a Bligh–Dyer extraction is recommended as
the best approach (Gibellini et al. 2009).
METABOLOME ANALYSIS
By far the most popular platform for quantiﬁcation
of analytes at a concentration ranging from sub-
picomolar to molar levels is mass spectrometry in
combination with liquid chromatography (LC–MS),
which enables rapid detection of a variety of soluble
analytes in a complex sample (Dunn et al. 2005). The
combination with liquid chromatography reduces
the complexity of the mass spectrum at each time
along the chromatographic run, potentially separates
isomers, and reduces undesired side-eﬀects such as
ion suppression (the presence of one compound
strongly aﬀecting the signal of another metabolite).
It also provides a characteristic retention time for
each metabolite, which assists in distinguishing the
compound and determining its general chemical
properties. The increase in sensitivity and resolution
of LC–MS achieved in recent years, most notably
with the introduction of the Orbitrap (Hardman and
Makarov, 2003), allows for the reliable detection
of even those metabolites present at small concen-
trations in a diverse and variable biological matrix.
Continuing improvements of mass spectrometry
technology will keep pushing the limits of detect-
ability even further (Han et al. 2008).
LC–MS has already been successfully applied to
a wide variety of organisms, most notably plants
and bacteria (Fiehn, 2001; Kell, 2004). A review of
recently published results indicates that a single
experiment can quantify between 100 and 200
metabolites in whole-cell extracts (Atherton et al.
2006; Dunn et al. 2008), corresponding to roughly
10% of the predicted core metabolism. Such a ﬁgure
stresses the need for more comprehensive techniques
to generate an overview of the full complexity of
the metabolome. For example, a more satisfactory
coverage with LC–MS can be achieved by combin-
ing measurements from diﬀerent chromatographic
separation techniques (reversed phase chromato-
graphy, hydrophilic interaction chromatography,
and ion pair chromatography). Additionally, the cur-
rent use of LC–MS does not allow for quantiﬁcation
of all detectedmetabolites (although quantiﬁcation of
selected compounds is possible using C13-labelled
standards). This is partly solved by additional
measurements using nuclear magnetic resonance
spectrometry, which oﬀers the ability to quantify
highly abundant metabolites. In Table 1 (Atherton
et al. 2006; van der Werf et al. 2007) a current
overview of the advantages and disadvantages of
commonly used analytical techniques is provided,
including an estimated number of identiﬁablemetab-
olites and their applicability or popularity within the
ﬁeld of metabolomics.
BIOINFORMATICS CHALLENGES
The sensitivity and resolution currently achieved
in mass spectrometry enables the use of complex
samples in elaborate experiments (e.g. collecting
samples along ﬁnely resolved time-series). These
can potentially yield large informative datasets about
parasite physiology very rapidly, but their interpret-
ation will require extensive bioinformatics eﬀorts.
Compared with gene expressionmicroarrays, metab-
olite mass spectra are far more complex and im-
possible to interpret manually on a large scale. For
example, deconvolution of the detected signals is
not yet an established routine operation.
Data generated by mass spectrometry platforms
contain large amounts of signals, few of which can
be identiﬁed by database matching (Fig. 4A). Many
of the unidentiﬁed signals correspond to analyte
derivatives (e.g. isotope peaks, adducts, fragments,
multiply charged molecules) and are of interest for
the identiﬁcation of signals, but not for the biological
interpretation of the measurements. In order to ease
identiﬁcation, reduce false positives and locate
novel analytes, these signals need to be tagged in the
data. Such procedures are already well-established
for GC-MS data, but are lacking for LC-MS data.
The combination of LC–MS with complex exper-
iments such as high-resolution time series ormultiple
perturbations helps achieving this aim (Tautenhahn
et al. 2007). Using data-driven clustering based
on signal shape correlation and intensity patterns
across biological replicates, derivative signals can be
identiﬁed reliably. In our experiments onLeishmania
parasites we have found that over 60% of the detected
signals consist of derivatives (Decuypere et al. un-
published). Time series not only allow for determi-
nation of metabolome dynamics following drug
treatment or during cellular diﬀerentiation, but the
intensity correlation pattern among adjacent time
points can also be used for sensitive detection of
measurement artefacts or spurious ﬂuctuations in
metabolites levels (Fig. 4B).
Signals can be putatively identiﬁed by matching
them on mass to species-speciﬁc metabolite data-
bases such as LeishCyc (Doyle et al. 2009), com-
pound class-speciﬁc databases such as LipidMAPS
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Table 1. Each analytical technique suitable for metabolite proﬁling has speciﬁc strengths and weaknesses. Generally, a single analytical method achieves a
coverage of roughly 5–10% of the expected metabolome, which can be extended by use of a combination of complementary analytical techniques (van der Werf
et al. 2007). The number presented in the column ‘metabolites measured’ provides a rough estimate of the number of metabolites that can be identiﬁed using
the described analytical method (*, using a single chromatographic column).
Analytical platform Major advantages Major disadvantages
Metabolites
measured Applications
‘Single ’ detection techniques
Nuclear Magnetic Resonance
(NMR)
$ detection independent of
ionisation
$ structural characterization power
$ long acquisition time
$ low resolution and sensitivity
20–50 $ fast screening method for
abundant metabolites
$ de novo identiﬁcation
Mass Spectrometry (MS) $ fast and sensitive detection of
metabolite masses
$ requires ions for detection
$ competitive ionisation of metabolites
in complex mixtures leads to
ionization suppression






(separation based on volatility)
$ good separation eﬃciency
$ low-cost and easy-to-operate system
$ excellent deconvolution and
metabolite identiﬁcation software
$ derivatisation increases number of
detectable metabolites
$ metabolites need to be volatile and
thermostable, diﬃcult for higher
mass molecules or molecules not
easily rendered volatile
$ derivatization includes more sample
handling, adds up in time and
generates more analytical variance




(separation based on chemical in-
teraction)
$ excellent versatility due to broad
range of columns with diﬀerent
chemical properties
$ good separation eﬃciency
$ good dynamic range
$ potentially separates isomers




(separation based on mass-to-
charge ratio)
$ versatile and fast method
$ good separation eﬃciency
$ low running costs
$ barely used in comprehensive
metabolomics analysis
50–150 $ mainly complementary
metabolomics technique, i.e. when
a major fraction of the sample
consists of polar and ionic
metabolites
















(Fahy et al. 2007), and contaminant databases, the
latter allows removal of typical impurities and buﬀer
components often detected in metabolomics exper-
iments (Keller et al. 2008). Formany samples it is also
useful to speciﬁcally search for computer-generated
lists of, for example, possible di- and tripeptides.
Together, this set of databases is a best ﬁrst guess
of the identity of the expected metabolites for a
Leishmania sample, and results in most cases in a
single chemical formula per signal (Fig. 4C).
Remaining unidentiﬁed compounds can then be
matched iteratively to more comprehensive data-
bases, including KEGG (Kanehisa et al. 2002),
Metlin (Smith et al. 2005), the Human Metabolome
Database (Wishart et al. 2007) or PubChem (Wang
et al. 2009), in roughly this order. These larger data-
bases tend to give more spurious hits, and careful
manual curation of the results is required. The
concurrent use of gas chromatography coupled to
mass spectrometry (GC–MS) in a comprehensive
platformwill greatly enhance the unambiguous iden-
tiﬁcation of metabolites. The stable retention times
produced with this method and the existence of li-
braries containing retention time information for a
huge array of analytes allows almost complete auto-
mation of this process (Pasikanti et al. 2008).
The highmass accuracy has additional advantages.
An area of particular interest for parasite metab-
olomics is the ab initio extension of the metabolic
network (Fig. 4D): based on the extremely accurate
mass information provided by the newest mass
spectrometers, it is possible to identify potential
metabolic transformations connecting the observed
mass peaks (Breitling et al. 2006). These hypothetical
connections between metabolites can be used to
















































































































false negatives, fill in iteratively
Fig. 4. Illustrations of some bioinformatics challenges for metabolomics data. (A) Mass spectrometry data contain a
large amount of signals, most of which can be identiﬁed as derivatives of a metabolite of interest (e.g. isotopes, adducts).
Data-driven reduction approaches help to reveal these derivative signals and reduce the annotation burden. (B) Time
series data can reveal metabolite dynamics following drug treatment or during diﬀerentiation, but also provide
important validation of observed expression levels. Here 6 biological replicates with (dashed) and without (solid)
perturbation are tracked over 4 time points for two metabolites, providing insight into their dynamic response to
perturbation. (C) After the applied deconvolution approaches, the detected compounds need to be identiﬁed. The graph
shows how the use of speciﬁc databases (y10.000 compounds; light-grey bars), in combination with higher mass
accuracy, results in a drastically lower number of false positives compared to using the comprehensive PubChem
database (more than 40 million compounds; dark-grey bars), ; this can signiﬁcantly reduce the burden of manual
curation. Interestingly, PubChem will always result in a match, while the collection of databases does not (false
negatives ; number of matches smaller than 1). To ﬁll in the gaps, the remaining unidentiﬁed signals are iteratively
assigned putative identities using progressively less speciﬁc databases. The resulting putative identiﬁcations then need
to be veriﬁed with orthogonal identiﬁcation techniques (e.g. fragmentation studies). (D) Using the observed exact mass
diﬀerences between metabolites it is possible to organise the observations in hypothetical metabolic networks by linking
them with a discrete set of biochemical transformations, further facilitating the interpretation process.
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compounds, to highlight connected areas of the
metabolome that show concerted changes in response
to a perturbation, such as drug treatment or cellular
diﬀerentiation, and to expand the computational
genome-based reconstructions of the metabolic
network to include novel pathways that may be
species-speciﬁc (Breitling et al. 2008). This may be
particularly relevant for Leishmania : after all,
roughly 1000 genes are speciﬁc to this genus, and
only very few of them have been functionally char-
acterized (Peacock et al. 2007). The network context
can also be used to support identiﬁcations of meta-
bolites (Rogers et al. 2009), which is further supported
by the combination with tandem mass spectrometry
fragmentation patterns (Bocker et al. 2008).
FUTURE PERSPECTIVE
Once metabolomics has been established as a routine
tool for Leishmania research, the next challenge will
be the integration of data across the various mol-
ecular levels. A comprehensive understanding of
Leishmania diversity is likely to require work at
the genome, proteome and metabolome levels in a
uniﬁed framework. With the current technological
advances, such a framework has come within reach.
The new genome sequencing technologies developed
over the past years, allow whole genome comparative
analyses of multiple strains of a given species. We
expect that the integration of global genomic and
metabolomic properties will result in unprecedented
insight into parasite diversity at the molecular level.
The exploitation of the resulting systems-wide view
and its eﬀective translation to treatment strategies
will require new alliances between specialized high-
tech centres, developing advanced measurement
technologies, and institutions engaged in the ﬁeld, at
the frontline of infectious disease research. A ﬁrst
initiative for post-genomic integration in Leishmania
research is the GeMInI consortium (http://
www.leishrisk.net/gemini), which brings together
next generation sequencing and high-performance
metabolomics on drug-sensitive and resistant
Leishmania donovani clinical isolates.
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